Boston Scientific (Boston Scientific) Cash-to-Debt

: 0.09 (As of Dec. 2023)

View and export this data going back to 1992. Start your Free Trial

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Boston Scientific's cash to debt ratio for the quarter that ended in Dec. 2023 was 0.09.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Boston Scientific couldn't pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Boston Scientific's Cash-to-Debt or its related term are showing as below:

BSX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.02 Med: 0.07 Max: 0.2
Current: 0.09

During the past 13 years, Boston Scientific's highest Cash to Debt Ratio was 0.20. The lowest was 0.02. And the median was 0.07.

BSX's Cash-to-Debt is ranked worse than
92.81% of 862 companies
in the Medical Devices & Instruments industry
Industry Median: 2.03 vs BSX: 0.09

Boston Scientific Cash-to-Debt Historical Data

The historical data trend for Boston Scientific's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Boston Scientific Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

0.02

0.18

0.20

0.10

0.09

Boston Scientific Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial															0.10	0.06	0.05	0.10	0.09

Competitive Comparison

For the Medical Devices subindustry, Boston Scientific's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Boston Scientific Cash-to-Debt Distribution

For the Medical Devices & Instruments industry and Healthcare sector, Boston Scientific's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Boston Scientific's Cash-to-Debt falls into.

Boston Scientific Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Boston Scientific's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	865	/	(531	+	8961)
	=	0.09

Boston Scientific's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	865	/	(531	+	8961)
	=	0.09

Boston Scientific (NYSE:BSX) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Boston Scientific Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Boston Scientific's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Boston Scientific (Boston Scientific) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Boston Scientific Corp (NYSE:BSX) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

BSX:Mexico 1BSX:Italy BSX:Germany BSX:Germany BSX:Germany B1SX34:Brazil BSXC:Austria

Address

300 Boston Scientific Way, Marlborough, MA, USA, 01752-1234

Website

https://www.bostonscientific.com

Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.

Executives

Joseph Michael Fitzgerald	officer: SVP & President, Endovascular	C/O BOSTON SCIENTIFIC, 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA 01752-1234
Jeffrey B. Mirviss	officer: SVP&Pres, Periph Intervent	C/O BOSTON SCIENTIFIC CORPORATION, 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA 01752-1234
Wendy Carruthers	officer: SVP, Human Resources	C/O BOSTON SCIENTIFIC CORPORATION, 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA 01752-1234
Arthur C Butcher	officer: SVP&Pres, Endoscopy	C/O BOSTON SCIENTIFIC CORPORATION, 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA 01752
Michael F Mahoney	officer: President	BOSTON SCIENTIFIC CORPORATION, 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA 01752-1234
Vance R Brown	officer: SVP, GC and Corp. Secretary	C/O BOSTON SCIENTIFIC CORPORATION, 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA 01752
Charles J Dockendorff	director	COVIDIEN LTD., 15 HAMPSHIRE STREET, MANSFIELD MA 02048
Susan E Morano	director	C/O BOSTON SCIENTIFIC CORPORATION, 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA 01752
Jessica L Mega	director	2200 PENNSYLVANIA AVENUE, SUITE 800W, WASHINGTON DC 20037
Thepaut Eric Francis Yves	officer: SVP & Pres, Europe	C/O BOSTON SCIENTIFIC CORPORATION, 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA 01752
John Bradley Sorenson	officer: SVP, Glob Ops & Qual	C/O BOSTON SCIENTIFIC CORPORATION, 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA 01752
Jonathan Monson	officer: VP, Corp Controller and CAO	C/O BOSTON SCIENTIFIC CORPORATION, 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA 01752
Daniel J. Brennan	officer: EVP and CFO	BOSTON SCIENTIFIC CORPORATION, 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA 01752-1234
Nelda J Connors	director	BOSTON SCIENTIFIC CORPORATION, 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA 01752-1234
Scott Olson	officer: SVP & Pres, Rhythm Management	C/O BOSTON SCIENTIFIC CORPORATION, 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA 01752